Research Article | Open Access
The Association between Monocyte Surface CD163 and Insulin Resistance in Patients with Type 2 Diabetes
Aim. To investigate the association between monocyte CD163 and insulin resistance in patients with type 2 diabetes. Methods. One hundred sixty-six patients with type 2 diabetes without inflammatory or chronic kidney disease were recruited. The monocyte CD163 levels were measured by flow cytometry and soluble CD163 (sCD163) by ELISA. Insulin resistance was evaluated by the index of the homeostasis model assessment (HOMA-R). Results. The median sCD163 and monocyte CD163 expression levels were 582.9 (472.4–720.0) ng/ml and 6061 (4486–7876) mean fluorescent intensity (MFI), respectively. In a simple regression analysis, monocyte CD163 was inversely correlated with log [HOMA-R] (, ), and sCD163 was positively correlated with log [HOMA-R] (, ). In multiple regression analyses, monocyte CD163 was an independent contributor to log [HOMA-R] (, ) even after adjustment of various clinical factors for HOMA-R (, ), whereas sCD163 was not. Conclusions. Monocyte surface CD163 expression levels were more significantly associated with insulin resistance than sCD163 in patients with type 2 diabetes, suggesting a novel pathophysiological role of CD163.
Cluster differentiation (CD) 163, a scavenger receptor for the haptoglobin-hemoglobin (Hb-Hp) complex specifically expressed on monocyte/macrophage lineages, has been extensively studied in hemoglobin-iron metabolism . It belongs to the scavenger receptor cysteine-rich family, which is composed of a short transmembrane domain, a short cytoplasmic tail, and an extracellular domain . The Hb-Hp complex (formed by the binding of hemoglobin to haptoglobin) in the circulation binds to monocyte surface CD163, which is subsequently incorporated by endocytosis and degenerated by heme oxygenase-1 (HO-1) to iron-containing heme, with reduced toxic properties [3, 4].
Recently, CD163 was also recognized to play a crucial role in various inflammatory diseases . CD163 is cleaved from the surface of monocyte by metalloprotease tumor necrosis factor alpha (TNFα)-converting enzyme (TACE/ADAM17), and soluble form of CD163 (sCD163) is released into circulation in response to inflammatory stimuli . In fact, the serum sCD163 level was found to increase in severe sepsis , liver failure , and chronic inflammatory diseases such as rheumatoid arthritis and cancer . In some viral infections, such as HIV infections, serum sCD163 levels and CD163 expression levels on monocyte populations are recently known to be associated with clinical status and antiretroviral therapy [7-8]. Furthermore, sCD163 was also reported to be associated with insulin resistance, obesity, and atherosclerotic disease [9–13]. A large cohort study revealed that sCD163 was predictive of the onset of type 2 diabetes . These findings suggest the possible use of sCD163 as a biomarker for insulin resistance and glucose intolerance, induced by inflammation.
On the other hand, CD163 expression on the surface of monocytes, a precursor of macrophages, has not been fully investigated, even though monocytes (as well as macrophages) have been recognized as a key player in chronic inflammation. Under steady-state conditions, the expression of CD163 on monocytes is 10- to 15-fold less than that of macrophages . However, once an inflammatory stimulus is added, the response of monocyte CD163 has a similar trend to that of macrophages , which suggests that monocyte CD163 may be a useful marker for inflammation. There are few reports examining monocyte CD163 expression levels in diabetes. One report has demonstrated an increase in monocyte CD163 mRNA levels after very low calorie diet therapy (VLCD), with a decrease in sCD163 levels . Another study found lower levels of monocyte CD163 expression in patients with type 2 diabetes having vascular complications than in those without vascular complications . Furthermore, CD163 is actually expressed on monocyte cell surface especially in the CD14highCD16+ monocyte subpopulation that has been reported to exert predominantly anti-inflammatory functions [18, 19]. Most upregulators of CD163 expression on monocyte are anti-inflammatory cytokines such as IL-10 and glucocorticoids . These evidences evoke us of a concept that monocyte CD163 is a potential protective marker for insulin resistance. To date, the association between monocyte CD163 and insulin resistance is not well studied. Therefore, it is necessary to elucidate the pathophysiological role and clinical implication of monocyte CD163 for insulin resistance.
In the present study, we investigated whether cell surface CD163 expression levels on peripheral blood monocytes (PBMs) as well as the level of sCD163 (in blood circulation) are associated with insulin resistance using homeostasis model assessment (HOMA-R) in a cross-sectional study involving 166 patients with type 2 diabetes.
One hundred sixty-six patients (96 males and 70 females) with type 2 diabetes who were admitted to the Diabetes Center of the Osaka City University Hospital from 2012 to 2014 were recruited for this study. The diagnosis of diabetes was based on a previous history of diabetes or on criteria from the American Diabetes Association . Patients with serum creatinine levels >1.5 mg/dL, acute and chronic inflammatory diseases, and malignant disease were excluded from this study. Each subject provided written informed consent. The ethical review board of our institution approved the study protocol (Registration Number 164).
Ten patients were treated with sulfonylureas monotherapy, 8 with dipeptidyl peptidase-4 (DPP-4) inhibitor monotherapy, 15 with biguanide (metformin) monotherapy, 2 with mitiglinide monotherapy, none with thiazolidine (pioglitazone) monotherapy, 61 were treated with a combination of these oral antidiabetic drugs, and 16 with diet therapy alone. Thirty-one patients were treated with insulin injections and 29 with a combination of oral antidiabetic drugs and insulin injections; 40.3% of subjects were treated with angiotensin II receptor blocker (ARB) and 47.6% of subjects were treated with statins.
2.2. Measurement of Soluble CD163 (sCD163) in the Blood
Peripheral serum samples were collected after 8 h overnight fasting. Then, serum sCD163 was determined by enzyme-linked immune sorbent assay (ELISA) (Quantikine® ELISA human CD163 immunoassay, R&D Systems, Inc., Minneapolis, MN, USA) as previously reported . The intra-assay and interassay coefficients of variation of soluble CD163 were 3.5% and 4.1%, respectively.
2.3. Assessment of Monocyte Surface CD163 on Peripheral Blood Monocytes
For the assessment of cell surface CD163 levels on peripheral blood monocytes (monocyte CD163), 1 mL of peripheral whole blood was collected from each patient. Then, erythrocytes were lysed with lysing solution (lysing buffer, BD pharm Lyse™, BD Biosciences, San Diego, CA, USA) for 10 min; peripheral leukocytes were used in the assay. A fluorescent-conjugated monoclonal antibody against CD163 (phycoerythrin (PE) anti-human CD163 antibody, clone GHI/61, BioLegend Inc., San Diego, CA, USA) was used for labeling monocyte CD163. One hundred thousand-labeled leukocytes for each subject were measured by flow cytometry (BD FACSCanto™ flow cytometer, Becton Dickinson Biosciences, San Jose, CA, USA). Monocytes were first gated in a forward scatter and sideward scatter dot plot, and then the levels of CD163 mean florescent intensity (MFI) were measured within the monocyte gate.
2.4. Laboratory Measurements
Blood was drawn after an overnight fast; biochemical parameters were analyzed using standard laboratory methods as previously described . Glycated hemoglobin A1C (HbA1c) levels were estimated as National Glycohemoglobin Standardization Program equivalent values (%), using the conversion formula established by the Japan Diabetes Society. Serum immune-reactive insulin (IRI) levels and serum C-peptide levels were measured by an electrochemiluminescence immunoassay (Roche Diagnostics K.K., Tokyo, Japan). High sensitivity TNFα (hsTNFα) and high sensitivity C-reactive proteins (hsCRP) were measured using a commercial ELISA kit (Quantikine HS ELISA human TNFα immunoassay and Quantikine ELISA human C-reactive protein immunoassay, R&D Systems, Inc., Minneapolis, MN, USA).
2.5. Assessment of Insulin Resistance by Homeostasis Model Assessment (HOMA-R)
HOMA-R was calculated from the fasting plasma glucose (FPG) and fasting plasma insulin (FIRI) levels according to the following formula previously reported by Matthews et al. :
The HOMA-R index is a well-established insulin resistance index that is highly correlated with the insulin resistance index assessed by euglycemic hyperinsulinemic clamp, a gold standard technique for the evaluation of insulin resistance in type 2 diabetes [25–27].
2.6. Statistical Analysis
All values are the means ± SD or median (interquartile) as appropriate. Statistical analysis was performed using the JMP 10 (SAS Institute Inc., Cary, NC, USA). To analyze the relationships between monocyte CD163, sCD163, HOMA-R, and various clinical parameters, simple linear regression analyses or multiple regression analyses were performed as appropriate. Log transformations were performed to achieve a normal distribution and were utilized for regression analyses. values of <0.05 were considered to be statistically significant.
3.1. Clinical Characteristics of the Subjects
The clinical characteristics of all subjects are shown in Table 1. The mean age, duration of diabetes, and BMI were 61.0 ± 13.0 years, 13.6 ± 11.4 years, and 25.7 ± 5.5 kg/m2, respectively. Mean serum creatinine levels were 0.80 ± 0.23 mg/dL. The glycemic control was HbA1c 8.31 ± 1.66%. As an inflammatory cytokine, the median hsTNFα level was 1.57 pg/mL (interquartile ranged from 1.16–1.92 pg/mL), and the median hsCRP level was 604.3 ng/mL (interquartile ranged from 291.1–1681.5 ng/mL).
|Data are expressed as (%), mean ± SD, or median (interquartile range) as appropriate. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: glycated hemoglobin A1c; HOMA-R: homeostasis model assessment of insulin resistance; TC: total cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; FFA: free fatty acid; Cre: creatinine; ARB: angiotensin-II receptor antagonists; hsTNFα: high sensitive tumor necrosis factor alpha; hsCRP: high sensitive C reactive protein.|
3.2. Serum sCD163 and Monocyte CD163 Levels
The median serum sCD163 level was 582.9 ng/mL (interquartile ranged from 472.4 to 720.0 ng/mL), and the median monocyte CD163 levels were 6061 MFI (interquartile ranged from 4486 to 7876 MFI), as shown in Figures 1(a) and 1(b), respectively. The association between sCD163 and monocyte CD163 was not significant (, ). Serum sCD163 levels were significantly correlated with hsTNFα (, ). In contrast, monocyte CD163 levels showed a negative correlation trend with TNFα but were not statistically significant (, ). Both sCD163 and monocyte CD163 levels were not associated with hsCRP (, ; , , resp.).
3.3. Correlation between sCD163, Monocyte CD163, and Possible Clinical Factors Involved in Insulin Resistance Using HOMA-R
The association between possible clinical factors and insulin resistance was analyzed by simple regression analyses as shown in Table 2. BMI (, ), TG (, ), HDL-C (, ), hsTNFα (, ), and hsCRP (, ) were significantly associated with log-transformed HOMA-R values, respectively. Notably, sCD163 was significantly correlated with log [HOMA-R] (, ), and monocyte CD163 levels were inversely correlated with log [HOMA-R] (, ) (Figure 2).
|r: correlation coefficient by simple regression analysis. Log: log-transformed TG, FFA, hsTNFα, or hsCRP. The abbreviations are the same as shown in Table 1.|
3.4. Contributions of sCD163, Monocyte CD163, and Possible Clinical Factors Related to Insulin Resistance by HOMA-R and Multiple Regression Analysis
To explore the independent contribution of sCD163, monocyte CD163, and possible clinical factors to insulin resistance, multiple regression analyses were performed. Log [HOMA-R] was set as the dependent variable, and sCD163, monocyte CD163, and possible clinical factors such as age, sex, BMI, log [TG], HDL-C, Cre, log [hsTNFα], and log [hsCRP] were set as the independent variables as shown in Table 3. The monocyte CD163 (, ) as well as the BMI (, ) was found to be a statistically significant independent factor to log [HOMA-R] (, , as shown in Table 3). On the other hand, the significant contribution of sCD163 to log [HOMA-R] disappeared after adjusting for age, sex, BMI, and other factors (as in model 1 of Table 3).
|β: standard correlation coefficient by multiple regression analysis. R2: multiple coefficients of determination. Log: log-transformed TG, FFA, hsTNFα, or hsCRP. The abbreviations are the same as shown in Table 1.|
The present study demonstrated the inverse association of monocyte CD163 level in patients with type 2 diabetes having insulin resistance, even after adjusting for various clinical factors related to insulin resistance, as evaluated by HOMA-R in multivariate analysis as well as by univariate analysis. On the other hand, the serum sCD163 level was not significantly associated with insulin resistance in multivariate analysis after adjustment, despite a significant positive association with it in univariate analysis. Our findings provide the first demonstration of the stronger contribution of monocyte CD163 levels in the peripheral blood compared to the serum sCD163 level for insulin resistance in patients with type 2 diabetes, suggesting the possibility of its use as a novel clinical surrogate marker for insulin resistance and providing new insight into the role of CD163 in insulin resistance and inflammation.
Several previous studies have reported serum sCD163 levels in obesity and atherosclerotic disease and its association with insulin resistance [9–13]. The level of sCD163 was reported to be higher in subjects with obesity  and those with obese type 2 diabetes  compared to that in controls. Compared to the characteristics of the subjects in that study, our subjects were older in age, had lower BMI, and higher HbA1c levels. However, our data still showed the same trend of a significant association between sCD163 level and insulin resistance by HOMA-R. Taken together with those of the previous findings, the association between sCD163 and insulin resistance may be found in a wide range of glucose intolerance states, such as obese/impaired glucose tolerance for diabetic patients.
Regarding insulin resistance, the level of sCD163 was also reported to be associated with insulin resistance by HOMA-R in subjects with obesity and glucose intolerance [10, 12]. Of 95 healthy subjects, 65 were obese and 30 were normal weight. Zanni et al. revealed that sCD163 strongly correlated with HOMA-R (Spearman’s , ) and that such an association remained significant even after adjustment for age, sex, visceral adiposity, and inflammatory markers . Among the 234 participants, 96 had type 2 diabetes, 34 showed impaired glucose tolerance (IGT), and 104 had normal glucose tolerance (NGT). Groups were also matched for sex and BMI. Parkner et al demonstrated that sCD163 was independently associated with HOMA-R by both univariate analysis () and multiple regression analysis . Although our univariate analysis findings were also compatible with those studies, the association between sCD163 and insulin resistance is rather weak than monocyte CD163 in patients with type 2 diabetes. This is why such an association was not found after adjustment of possible clinical factors for insulin resistance in our multivariate analysis (Table 2). Interestingly, serum sCD163 levels were reported to predict the incidence of type 2 diabetes in a large prospective cohort study, in which 8849 general participants from Denmark were followed for 18 years . Recently, in a double-blind randomized control trial of 72 patients with type 2 diabetic patients, intake of DHA-enriched fish oil for 8 weeks induced a significant decrease in the level of sCD163 accompanied by a change in insulin resistance-associated parameters . These findings suggest that sCD163 is one of the biomarkers responsible for impaired glucose tolerance or insulin resistance induced by inflammation .
In our study, we focused on monocyte cell surface CD163 rather than sCD163, hypothesizing that monocyte surface CD163 might have a stronger anti-inflammatory effect. Currently, macrophages are categorized into two subsets, inflammatory macrophages (M1) with low CD163 expression and anti-inflammatory macrophages (M2) with high CD163 expression, which produce anti-inflammatory cytokines such as Interleukin-10 (IL-10) . Similarly, monocytes, which are thought to be a precursor of macrophages, are also divided into anti-inflammatory and proinflammatory subsets by functional classification. Anti-inflammatory monocyte subsets are speculated to differentiate into M2 macrophages. Most upregulators of CD163 expression on monocyte have been reported to be anti-inflammatory cytokines such as IL-10 and glucocorticoids . These recent findings suggest the possibly important role of monocyte CD163 in blood circulation. Previous studies measured CD163 mRNA levels in monocytes from the peripheral blood, which reflects the total transcription level of CD163 and, therefore, is not a direct estimate of the functional amount of CD163 [16, 17]. Based on these findings, we measured the expression of monocyte CD163 on the surface of monocytes by flow cytometry to more directly evaluate the functional amount of monocyte CD163 compared to that shown by CD163 mRNA or sCD163 levels.
As a result, monocyte surface CD163 was found to have a close inverse relationship with insulin resistance by HOMA-R, even after adjusting for other possible clinical factors related to insulin resistance, whereas sCD163 levels showed no association (Table 3). sCD163 is known to be produced from various tissue macrophages such as Kupffer cells, myeloid macrophages, and pulmonary macrophages, which indicates that sCD163 measurements reflect the total amount in the entire body. This may explain why sCD163 is a less sensitive marker for insulin resistance than monocyte CD163. Indeed, monocytes with low CD163 expression identified in our study can be considered to be a precursor of M1 macrophages located in local adipose tissue, which play an important role for insulin resistance . Therefore, our data suggests that measurements of monocyte CD163, rather than sCD163, serve as a better surrogate marker for pathophysiological impact in insulin resistance for patients with type 2 diabetes.
The mechanisms underlying the role of monocyte CD163 in insulin resistance were not determined from our clinical study. However, other studies provide some clues. One possibility is that oxidative stress induced by hyperglycemia and various factors in diabetes and/or insulin resistance may cause shedding of surface monocyte CD163 by TACE/ADAM17 activation, resulting in an increase of CD163low monocytes and, subsequently, an increase in preM1 and M1-like monocytes [30, 31]. This M1 predominant state in adipose tissue can lead to an increase in local inflammation and insulin resistance mediated by cytokines such as TNFα.
Another possibility is improved insulin resistance resulting from IL-10. The M2 macrophage, which is thought to differentiate from CD163high-expressed monocyte, produces IL-10 in local adipose tissue and skeletal muscles . For in vivo mice experiments, IL-10 administration was reported to restore glucose uptake decreased by IL-6 administration in skeletal muscle to that of the control level , suggesting an important role for cytokine-induced glucose uptake in skeletal muscles. These findings raise the possibility that monocytes in the peripheral blood having high levels of CD163 expression induce expression and/or activate M2 macrophages in skeletal muscles, resulting in an increase in the local production of IL-10 and glucose uptake in skeletal muscles. Further studies are needed to elucidate the mechanisms underlying the relationship between monocyte CD163 and insulin resistance in obese and diabetes.
There are a few limitations in our study. First, our study is of cross-sectional design and is therefore not able to draw conclusive causal relationship between monocyte CD163 and insulin resistance. Second, insulin resistance was evaluated by the simple surrogate index of HOMA-R, which is not a direct quantitative index of insulin-mediated glucose uptake in skeletal muscles and/or adipose tissue. However, HOMA-R has been established as an excellent surrogate marker for insulin resistance and has been used by many investigators as a surrogate marker for insulin resistance in patients with both obesity and type 2 diabetes with various conditions [24–27, 33]. Multifaceted medical intervention was performed in our diabetic subjects, since they were recruited from inpatients participating in educational program for diabetes. Thus, we can eliminate the possibility of any influence by various medical interventions in our findings.
In conclusion, the present study demonstrated the closer association between surface monocyte CD163-expressing monocytes from the peripheral blood, rather than serum sCD163 levels, and insulin resistance, independent of known clinical factors in patients with type 2 diabetes. These findings suggest not only the possible use of monocyte CD163 as a novel surrogate marker for insulin resistance in diabetes and/or obesity but also provide insight into the pathophysiological role of monocyte CD163 in the development of insulin resistance states. In order to clinically clarify the causal relationship between monocyte CD163 and insulin resistance, interventional trials for insulin resistance will be needed, in which monocyte CD163 will be evaluated with some cytokines (e.g., IL-6, IL-10, and/or TNFα) after intervention such as body weight reduction, exercise, and/or drugs (e.g., thiazolidinedione). Furthermore, animal models with monocyte specific overexpression or knockdown of CD163, if made in the future, might elucidate basic mechanisms between monocyte CD163 and insulin resistance.
Conflicts of Interest
The authors declare no conflicts of interest.
Reina Kawarabayashi performed all steps of this work. Koka Motoyama wrote the protocol, analyzed the data, and wrote the draft. Masanori Emoto managed all steps of the study and wrote and edited the draft. Miyuki Nakamura and Yuko Yamazaki contributed to the data collection and assays. Tomoaki Morioka, Katsuhito Mori, Shinya Fukumoto, Yasuo Imanishi, Atsushi Shioi, and Tetsuo Shoji recruited the subjects. Tomoaki Morioka, Katsuhito Mori, Tetsuo Shoji, Yasuo Imanishi, and Masaaki Inaba contributed to the discussion and critically reviewed/revised the manuscript. Koka Motoyama and Masanori Emoto are guarantors of this work, had full access to all data, and take responsibility for the integrity of the data and accuracy of the data analysis. All authors read and approved the final manuscript.
The authors acknowledge the excellent technical assistance of Mrs. Masayo Monden from the research laboratory in the Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine. This study was supported by a Grant-in-Aid for Scientific Research (C) (no. 15K08925) from the Japan Society for the Promotion of Science (to Koka Motoyama).
- M. Kristiansen, J. H. Graversen, C. Jacobsen et al., “Identification of the haemoglobin scavenger receptor,” Nature, vol. 409, no. 6817, pp. 198–201, 2001.
- H. J. Moller, “Soluble CD163,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 72, no. 1, pp. 1–13, 2012.
- J. H. Thomsen, A. Etzerodt, P. Svendsen, and S. K. Moestrup, “The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 523652, 11 pages, 2013.
- N. G. Abraham and G. Drummond, “CD163-mediated hemoglobin-heme uptake activates macrophage HO-1, providing an antiinflammatory function,” Circulation Research, vol. 99, no. 9, pp. 911–914, 2006.
- S. Gaini, O. G. Koldkjaer, S. S. Pedersen, C. Pedersen, S. K. Moestrup, and H. J. Møller, “Soluble haemoglobin scavenger receptor (sCD163) in patients with suspected community-acquired infections,” APMIS, vol. 114, no. 2, pp. 103–111, 2006.
- A. Hiraoka, N. Horiike, S. M. Akbar, K. Michitaka, T. Matsuyama, and M. Onji, “Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure,” Journal of Gastroenterology, vol. 40, no. 1, pp. 52–56, 2005.
- J. Ananworanich, S. J. Kerr, T. Jaimulwong et al., “Soluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children,” Journal of Virus Eradication, vol. 1, no. 3, pp. 196–202, 2015.
- L. C. Ndhlovu, M. L. D'antoni, J. Ananworanich et al., “Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-naive HIV-infected Thais,” Journal of Neuroimmunology, vol. 288, pp. 25–33, 2015.
- J. A. Moreno, A. Ortega-Gomez, S. Delbosc et al., “In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis,” European Heart Journal, vol. 33, no. 2, pp. 252–263, 2012.
- M. V. Zanni, T. H. Burdo, H. Makimura, K. C. Williams, and S. K. Grinspoon, “Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects,” Clinical Endocrinology, vol. 77, no. 3, pp. 385–390, 2012.
- L. P. Sorensen, T. Parkner, E. Sondergaard, B. M. Bibby, H. J. Moller, and S. Nielsen, “Visceral obesity is associated with increased soluble CD163 concentration in men with type 2 diabetes mellitus,” Endocrine Connections, vol. 4, no. 1, pp. 27–36, 2015.
- T. Parkner, L. P. Sorensen, A. R. Nielsen et al., “Soluble CD163: a biomarker linking macrophages and insulin resistance,” Diabetologia, vol. 55, no. 6, pp. 1856–1862, 2012.
- O. Toupchian, G. Sotoudeh, A. Mansoori et al., “Effects of DHA-enriched fish oil on monocyte/macrophage activation marker sCD163, asymmetric dimethyl arginine, and insulin resistance in type 2 diabetic patients,” Journal of Clinical Lipidology, vol. 10, no. 4, pp. 798–807, 2016.
- H. J. Moller, R. Frikke-Schmidt, S. K. Moestrup, B. G. Nordestgaard, and A. Tybjaerg-Hansen, “Serum soluble CD163 predicts risk of type 2 diabetes in the general population,” Clinical Chemistry, vol. 57, no. 2, pp. 291–297, 2011.
- P. Ugocsai, S. Barlage, A. Dada, and G. Schmitz, “Regulation of surface CD163 expression and cellular effects of receptor mediated hemoglobin-haptoglobin uptake on human monocytes and macrophages,” Cytometry Part A, vol. 69, no. 3, pp. 203–205, 2006.
- J. Kračmerová, L. Rossmeislová, Z. Kováčová et al., “Soluble CD163 is associated with CD163 mRNA expression in adipose tissue and with insulin sensitivity in steady-state condition but not in response to calorie restriction,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 3, pp. E528–E535, 2014.
- D. Min, B. Brooks, J. Wong et al., “Monocyte CD163 is altered in association with diabetic complications: possible protective role,” Journal of Leukocyte Biology, vol. 100, no. 6, pp. 1375–1383, 2016.
- C. Buechler, M. Ritter, E. Orsó, T. Langmann, J. Klucken, and G. Schmitz, “Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli,” Journal of Leukocyte Biology, vol. 67, no. 1, pp. 97–103, 2000.
- M. Moniuszko, A. Bodzenta-Lukaszyk, K. Kowal, D. Lenczewska, and M. Dabrowska, “Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients,” Clinical Immunology, vol. 130, no. 3, pp. 338–346, 2009.
- K. Kowal, R. Silver, E. Slawinska, M. Bielecki, L. Chyczewski, and O. Kowal-Bielecka, “CD163 and its role in inflammation,” Folia Histochemica et Cytobiologica, vol. 49, no. 3, pp. 365–374, 2011.
- American Diabetes Association, “Standards of medical care in diabetes–2014,” Diabetes Care, vol. 37, Supplement 1, pp. S14–S80, 2014.
- A. P. Levy, K. R. Purushothaman, N. S. Levy et al., “Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability,” Circulation Research, vol. 101, no. 1, pp. 106–110, 2007.
- Y. Yamazaki, M. Emoto, T. Morioka et al., “Clinical impact of the leptin to soluble leptin receptor ratio on subclinical carotid atherosclerosis in patients with type 2 diabetes,” Journal of Atherosclerosis and Thrombosis, vol. 20, no. 2, pp. 186–194, 2013.
- D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985.
- M. Emoto, Y. Nishizawa, K. Maekawa et al., “Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas,” Diabetes Care, vol. 22, no. 5, pp. 818–822, 1999.
- H. Yokoyama, M. Emoto, S. Fujiwara et al., “Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients,” Diabetes Care, vol. 26, no. 8, pp. 2426–2432, 2003.
- H. Yokoyama, M. Emoto, S. Fujiwara et al., “Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 3, pp. 1481–1484, 2004.
- G. Chinetti-Gbaguidi, S. Colin, and B. Staels, “Macrophage subsets in atherosclerosis,” Nature Reviews Cardiology, vol. 12, no. 1, pp. 10–17, 2015.
- C. N. Lumeng, J. L. Bodzin, and A. R. Saltiel, “Obesity induces a phenotypic switch in adipose tissue macrophage polarization,” The Journal of Clinical Investigation, vol. 117, no. 1, pp. 175–184, 2007.
- A. Etzerodt, M. B. Maniecki, K. Moller, H. J. Moller, and S. K. Moestrup, “Tumor necrosis factor α-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163,” Journal of Leukocyte Biology, vol. 88, no. 6, pp. 1201–1205, 2010.
- A. Etzerodt and S. K. Moestrup, “CD163 and inflammation: biological, diagnostic, and therapeutic aspects,” Antioxidants & Redox Signaling, vol. 18, no. 17, pp. 2352–2363, 2013.
- H. J. Kim, T. Higashimori, S. Y. Park et al., “Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo,” Diabetes, vol. 53, no. 4, pp. 1060–1067, 2004.
- T. M. Wallace and D. R. Matthews, “The assessment of insulin resistance in man,” Diabetic Medicine, vol. 19, no. 7, pp. 527–534, 2002.
Copyright © 2017 Reina Kawarabayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.